Tenofovir HIV PrEP causes no long-term harm to kidneys
Action needed to tackle co-infection with HIV and visceral leishmaniasis in India
Low vitamin D concentrations associated with poor clinical and virological outcomes among people starting HIV therapy
People living with HIV at higher risk of cancers caused by smoking or viruses, but not all cancers
New US guidelines recommend PrEP
Daily dosing key to the efficacy of tenofovir-based HIV PrEP
New booklet from NAM: Taking your HIV treatment
